RWLK REWALK ROBOTICS LTD

ReWalk Robotics to Discuss Medicare’s Preliminary Payment Determination for ReWalk Personal Exoskeleton

ReWalk Robotics to Discuss Medicare’s Preliminary Payment Determination for ReWalk Personal Exoskeleton

Conference Call on Wednesday, November 8, 2023, at 8:30 a.m. EST

MARLBOROUGH, Mass., and BERLIN, and YOKNEAM ILLIT, Israel, Nov. 07, 2023 (GLOBE NEWSWIRE) -- ReWalk Robotics Ltd. (Nasdaq: RWLK) (“ReWalk” or the “Company”), a leading provider of innovative technologies that enable mobility and wellness in rehabilitation and daily life for individuals with neurological conditions, today announced that that it has scheduled a conference call for Wednesday, November 8, 2023 at 8:30 a.m. EST, to discuss Medicare’s preliminary payment determination for the ReWalk Personal Exoskeleton.

On Friday, November 3, the Centers for Medicare & Medicaid Services (“CMS”) released an agenda for the upcoming Healthcare Common Procedure Coding System (“HCPCS”) meeting on November 29, 2023, which includes an item to discuss the Medicare payment determination for the ReWalk Personal Prosthetic Exoskeleton system and provides a preliminary payment determination of $94,617.

Larry Jasinski, Chief Executive Officer, Jeannine Lynch, Vice President of Market Access and Strategy, and Mike Lawless, Chief Financial Officer, will host a conference call at 8:30 a.m. EST to discuss the potential impact of this announcement. To access the call, analysts and investors may utilize the following:

Toll free (U.S.)1-833-316-0561
International (U.S)1-412-317-0690
Germany0800-6647650
Israel1-80-9212373
Access CodePlease reference the “ReWalk Robotics Ltd. Call”
  

The conference call will be webcast live and the webcast can be accessed through a link on the Company’s website at rewalk.com in the "Investors" section, or through the following link: . An archived webcast will also be available on the company's website.

About ReWalk Robotics Ltd.

ReWalk Robotics Ltd. is a medical device company that designs, develops, and commercializes innovative technologies that enable mobility and wellness in rehabilitation and daily life for individuals with neurological conditions. ReWalk’s mission is to fundamentally change the quality of life for these individuals through the creation and development of market leading technologies. Through its recent acquisition of AlterG, Inc., ReWalk has added anti-gravity systems to its growing portfolio of products. Founded in 2001, ReWalk has operations in the United States, Israel, and Germany. For more information on the ReWalk systems, please visit . For more information on the AlterG systems, please visit .

ReWalk® and ReStore® are registered trademarks of ReWalk Robotics Ltd. in the United States and other jurisdictions. AlterG® is a registered trademark of AlterG, Inc. in the United States and other jurisdictions.

ReWalk Media Relations:

LifeSci Communications

E:



ReWalk Investor Contact:

Mike Lawless

Chief Financial Officer

ReWalk Robotics Ltd

E: 



EN
07/11/2023

Underlying

To request access to management, click here to engage with our
partner Phoenix-IR's CorporateAccessNetwork.com

Reports on REWALK ROBOTICS LTD

 PRESS RELEASE

Lifeward Announces Reverse Share Split

Lifeward Announces Reverse Share Split Reverse split initiated as Lifeward enters strategic partnership agreement and repositions as MedTech innovation company HUDSON, Mass. and YOKNEAM ILLIT, Israel, Feb. 20, 2026 (GLOBE NEWSWIRE) -- Lifeward Ltd. (Nasdaq: LFWD) (“Lifeward” or the “Company”), a global leader in innovative medical technology designed to transform the lives of people with physical limitations or disabilities, today announced that effective with the open of the market on February 24, 2026, the Company will complete a 1-for-12 reverse split of its ordinary shares. On Janu...

 PRESS RELEASE

Lifeward’s ReWalk™ Personal Exoskeleton Now Covered by Aetna, Coverage...

Lifeward’s ReWalk™ Personal Exoskeleton Now Covered by Aetna, Coverage Expands to Include Three of the Largest Medicare Advantage Insurers Aetna joins Humana and United Healthcare in providing Medicare Advantage coverage for beneficiaries who meet medical necessity criteria for the ReWalk Personal Exoskeleton Together, these three national Medicare Advantage insurers represent approximately 16 million beneficiaries across the United States HUDSON, Mass. and YOKNEAM ILLIT, Israel, Feb. 17, 2026 (GLOBE NEWSWIRE) -- Lifeward Ltd. (Nasdaq: LFWD) (“Lifeward” or the “Company”), a global lead...

 PRESS RELEASE

Lifeward Enters Transformative Strategic Investment and Partnership Ag...

Lifeward Enters Transformative Strategic Investment and Partnership Agreement with Oramed to Create a Diversified Biomedical Innovation Company Positions Lifeward as a MedTech platform with a clear path to cashflow positive and long-term Biotech upside potential Up to $47 million strategic investment from Oramed and another investor is intended to provide Lifeward cash runway to profitability and diversify its portfolio across MedTech and BioTech Lifeward acquires Oramed’s clinical-stage Protein Oral Delivery (POD™) technology adding exposure to a large, long-term Biotech market opportuni...

 PRESS RELEASE

Lifeward Appoints Bob Marshall as Chairman of the Board

Lifeward Appoints Bob Marshall as Chairman of the Board MARLBOROUGH, Mass. and YOKNEAM ILLIT, Israel, Dec. 19, 2025 (GLOBE NEWSWIRE) -- ., (Nasdaq: LFWD) (“Lifeward” or the “Company”), a global leader in innovative medical technology designed to transform the lives of people with physical limitations or disabilities, announced today that its Board of Directors has appointed Bob Marshall as Chairman of the Board, effective January 1, 2026. He replaces Joseph Turk, who will transition off the Board in connection with his new position at Fresenius Medical Care. “On behalf of the Board and e...

 PRESS RELEASE

Lifeward Expands International Distribution of its ReWalk® Personal Ro...

Lifeward Expands International Distribution of its ReWalk® Personal Robotic Exoskeleton into Mexico, Thailand, and the United Arab Emirates Distribution agreement with Singapore-based Verita Neuro will provide patients the ReWalk Personal Exoskeleton as part of its multi-layered treatment modalities New delivery model for ReWalk will integrate in-patient training and rehabilitation to support clinical adoption in physical rehabilitation settings Over 7 million survivors of spinal cord injury (SCI) globally could potentially benefit from ReWalk, an estimated $1.75 billion total addressable...

ResearchPool Subscriptions

Get the most out of your insights

Get in touch